Jim Simons Aligos Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024
SELL
$0.35 - $1.07 $13,797 - $42,180
-39,421 Reduced 4.88%
768,839 $269,000
Q1 2024

May 13, 2024
BUY
$0.64 - $1.13 $203,712 - $359,678
318,300 Added 64.96%
808,260 $792,000
Q4 2023

Feb 13, 2024
BUY
$0.56 - $0.8 $94,416 - $134,880
168,600 Added 52.46%
489,960 $325,000
Q3 2023

Nov 14, 2023
SELL
$0.71 - $1.06 $77,528 - $115,746
-109,195 Reduced 25.36%
321,360 $240,000
Q2 2023

Aug 11, 2023
SELL
$0.89 - $1.36 $19,851 - $30,334
-22,305 Reduced 4.93%
430,555 $418,000
Q1 2023

May 12, 2023
SELL
$0.87 - $2.11 $69,078 - $167,534
-79,400 Reduced 14.92%
452,860 $396,000
Q4 2022

Feb 13, 2023
SELL
$0.89 - $28.0 $176,520 - $5.55 Million
-198,338 Reduced 27.15%
532,260 $507,000
Q3 2022

Nov 14, 2022
SELL
$1.06 - $27.5 $182,852 - $4.74 Million
-172,502 Reduced 19.1%
730,598 $804,000
Q2 2022

Aug 12, 2022
BUY
$1.04 - $2.14 $562,417 - $1.16 Million
540,786 Added 149.26%
903,100 $1.09 Million
Q1 2022

May 13, 2022
BUY
$2.08 - $12.2 $640,253 - $3.76 Million
307,814 Added 564.8%
362,314 $779,000
Q4 2021

Feb 11, 2022
BUY
$11.48 - $17.69 $14,924 - $22,997
1,300 Added 2.44%
54,500 $647,000
Q3 2021

Nov 12, 2021
BUY
$14.57 - $17.72 $775,124 - $942,703
53,200 New
53,200 $825,000

Others Institutions Holding ALGS

# of Institutions
32
Shares Held
37.7M
Call Options Held
1.4K
Put Options Held
300
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email